Motivational Interviewing for encouraging quit attempts among unmotivated smokers: study protocol of a randomized, controlled, efficacy trial by Catley, Delwyn et al.
STUDY PROTOCOL Open Access
Motivational Interviewing for encouraging quit
attempts among unmotivated smokers: study
protocol of a randomized, controlled, efficacy trial
Delwyn Catley1*, Kari Jo Harris2, Kathy Goggin1, Kimber Richter3, Karen Williams4, Christi Patten5, Ken Resnicow6,
Edward Ellerbeck3, Andrea Bradley-Ewing1, Domonique Malomo1 and Robin Liston1
Abstract
Background: Although the current Clinical Practice Guideline recommend Motivational Interviewing for use with
smokers not ready to quit, the strength of evidence for its use is rated as not optimal. The purpose of the present
study is to address key methodological limitations of previous studies by ensuring fidelity in the delivery of the
Motivational Interviewing intervention, using an attention-matched control condition, and focusing on unmotivated
smokers whom meta-analyses have indicated may benefit most from Motivational Interviewing. It is hypothesized
that MI will be more effective at inducing quit attempts and smoking cessation at 6-month follow-up than brief
advice to quit and an intensity-matched health education condition.
Methods/Design: A sample of adult community resident smokers (N = 255) who report low motivation and
readiness to quit are being randomized using a 2:2:1 treatment allocation to Motivational Interviewing, Health
Education, or Brief Advice. Over 6 months, participants in Motivational Interviewing and Health Education receive 4
individual counseling sessions and participants in Brief Advice receive one brief in-person individual session at
baseline. Rigorous monitoring and independent verification of fidelity will assure the counseling approaches are
distinct and delivered as planned. Participants complete surveys at baseline, week 12 and 6-month follow-up to
assess demographics, smoking characteristics, and smoking outcomes. Participants who decide to quit are provided
with a self-help guide to quitting, help with a quit plan, and free pharmacotherapy. The primary outcome is
self-report of one or more quit attempts lasting at least 24 hours between randomization and 6-month follow-up.
The secondary outcome is biochemically confirmed 7-day point prevalence cessation at 6-month follow-up.
Hypothesized mediators of the presumed treatment effect on quit attempts are greater perceived autonomy
support and autonomous motivation. Use of pharmacotherapy is a hypothesized mediator of Motivational
Interviewing’s effect on cessation.
Discussion: This trial will provide the most rigorous evaluation to date of Motivational Interviewing’s efficacy for
encouraging unmotivated smokers to make a quit attempt. It will also provide effect-size estimates of MI’s impact
on smoking cessation to inform future clinical trials and inform the Clinical Practice Guideline.
Trial registration: ClinicalTrials.gov NCT01188018
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Background
Tobacco use is the primary cause of preventable diseases
in the United States. In 2009, an estimated 46.6 million
adults in the United States were current smokers [1].
Smoking in the US accounts for about 443,000 deaths
yearly, approximately 5.1 million in years of potential life
lost, and $96.8 billion in productivity losses [2]. Redu-
cing the prevalence of smoking remains one of the coun-
try’s most important public health goals [1,2].
To reduce the health and social consequences of
tobacco use, it is essential to reduce the decades-long
lag between initiation of regular smoking and cessation.
Many smokers will smoke for 20–30 years before quit-
ting [3]. The sooner a smoker stops, the greater the
gains in life expectancy [4]. Although most smokers are
“interested” in quitting smoking [5], approximately 40%
are not planning on quitting in the next 6-months and
another 40% have no plans to quit in the next month
[6]. Unfortunately, established clinical smoking cessation
interventions focus on those in the remaining 20% that
are ready and seeking assistance to quit. For example,
many tobacco quit-lines in the United States, require
callers to be ready to quit before comprehensive services
are provided [7]. Likewise, primary care physicians are
less likely to counsel patients to quit, or refer them to
counseling, if they believe the patient is not ready to quit
[8,9]. Given those not ready to quit comprise a large ma-
jority of the smoking population, proactive intervention
with less motivated smokers could have a significant
public health impact, even if such intervention had only
moderate efficacy [10].
One promising approach to encourage cessation
among less motivated smokers is Motivational Inter-
viewing (MI), a treatment approach that emerged from
the alcohol and drug treatment literature that focuses on
fostering motivation for, and commitment to behavior
change. MI has been defined as a collaborative, person-
centered form of guiding to elicit and strengthen motiv-
ation for change [11]. Principles of MI include using a
collaborative style, eliciting individuals’ reasons for
change rather than persuading, and supporting auton-
omy so that individuals do not feel pressured to change
and can feel autonomously or “internally” motivated.
These principles are manifested in communication
methods (e.g., open-ended questions, affirming, and re-
flective listening) that are used to strategically elicit and
enhance the individual’s elaboration of “change talk”
(statements in the direction of making a change) and in-
crease their awareness of the discrepancy between their
current behavior and their perception of what would be
ideal behavior. These strategies are thought to be more
effective than questioning, persuading, or giving advice.
Meta-analyses have indicated that MI-based interven-
tions have modest positive effects on smoking cessation
relative to interventions such as brief advice to quit
[12-14]. However, the Clinical Practice Guideline and several
meta-analyses have noted significant deficiencies in the
evidence base [12,13,15]. Significant limitations of the
existing literature include the inadequate evidence of
intervention fidelity, the lack of research comparing MI
to alternative interventions of equal intensity, and the
lack of focus on the role of motivation to quit and mo-
tivation and quit attempts as outcomes [12,13]. Evidence
of fidelity to MI principles is essential for internal valid-
ity and because null effects could be due to “Type 3
error” (i.e., low quality implementation rather than inef-
fective treatment), yet prior MI studies have rarely
included the use of a validated instrument for assessing
MI adherence [12].
Equally important for advancing the research on MI is
whether the positive effects observed in prior studies
can be attributed to the benefits of MI or simply to the
greater duration of contact with participants. Teasing
out counseling approach effects from general attention
effects is critical given the cost and complexity of imple-
menting an MI intervention. For example, studies have
shown that significant training and practice is necessary
for MI to be properly implemented [16] and there is a
lack of research comparing MI with potentially more
straightforward but equally intensive interventions
(e.g. intensive health education) [12].
A third major concern with the existing evidence base
for MI is the lack of attention to the role of motivation.
Motivation mediates cessation outcomes and, according
to meta-analysis, MI may be more effective for low
motivated smokers [17]. Accordingly, there is also evi-
dence that cognitive-behavioral skills training may be
more effective than MI for smokers already motivated to
make a quit attempt [18]. Taken together, these findings
suggest that tailoring counseling style to motivational
level may be most effective.
The purpose of the present study is to conduct a ran-
domized controlled trial to examine the efficacy of MI
for inducing quit attempts among low motivated smo-
kers while addressing key limitations of prior studies.
The primary outcome will be the effect of MI on any
quit attempt by the 6-month follow-up relative to an
intensity-matched control condition (Health Education;
HE) and minimal intervention control condition (Brief
Advice to quit; BA). The secondary outcome is biochem-
ically confirmed 7-day point-prevalence cessation rates
at 6-month follow-up. Participants’ perceived autonomy
support from their counselor and autonomous motiv-
ation for quitting will be examined as mediators of any
treatment effect on quit attempts. Participants who
choose to set a quit date for a quit attempt will be
offered pharmacotherapy and pharmacotherapy use will
also be examined as a mediator of MI’s effect on
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cessation. In addition, the goal is to implement the MI
intervention with high fidelity verified with independent
coders using a validated coding scheme. The study uses
quit attempts rather than cessation as the primary out-
come to reduce the needed sample size. The study aims
to be a preliminary step toward a much larger trial that
will also include more highly motivated participants for
comparison and focus on smoking cessation as the main
outcome.
Methods/Design
Trial design
This is a multi-arm parallel group, randomized trial with
imbalanced randomization (2:2:1 for MI, HE, and BA,
respectively) being conducted in the United States.
Blinding of counselors is not feasible in this study. Parti-
cipants are informed that they will be randomly assigned
to one of three counseling approaches that differ in style
and/or number of sessions. Although participants can
differentiate whether they are in the BA versus MI or
HE because of the different number of sessions, they are
not informed in any way regarding the names, the na-
ture, or distinctions between HE and MI and therefore
will be blind to which of these two treatments they
receive.
Recruitment, participants, and setting
The study is being conducted at a single university-
based site in Kansas City, Missouri. The study protocol
is in compliance with the Helsinki Declaration and was
reviewed and approved by the Institutional Review
Board of the University of Missouri – Kansas City
(#0978). Smokers are recruited community-wide through
word of mouth, newspaper ads, flyers, billboards, inter-
net advertising, and physician referral using printed
cards. Recruitment materials invite participation in a
study “for smokers” or “smokers not quite ready to quit”
and provide a study phone number to call for more in-
formation. Potential participants who enquire about the
study are informed that the goal is to learn how best to
talk to smokers about their health. They are informed
that although their smoking will be discussed they will
not be required to quit. Eligibility criteria are being
18 years or older, English speaking, reporting smoking a
minimum of 1 cigarette per day, having a mailing ad-
dress and telephone number, willingness to participate
in all study components, not currently pregnant or plan-
ning to become pregnant in the next 6 months, not cur-
rently using a smoking cessation medication, not
planning to move from the metropolitan area in the next
6 months, and not currently motivated or ready to quit
smoking (defined as scoring 6 or less on a 0–10 point
scale of motivation to quit smoking and having no
intention to quit in the next 7 days). Potential
participants are pre-screened by phone and those likely
to be eligible are scheduled for a baseline visit at which
time they are re-screened and enrolled if eligible. After
the first 24 participants were enrolled, confirmation of
self-reported smoking status using a carbon monoxide
monitor (Bedfont Scientific piCO+SmokerlyzerW) was
added to the re-screen. Eligibility is determined by a CO
level of 7 ppm or higher [19,20].
Trial interventions
Motivational interviewing
MI consists of 4 sessions (baseline, week 6, week 12 and
week 18) of approximately 20 minutes each conducted
in-person (baseline and week 12) and over the phone
(week 6 and week 18). The 4-session schedule is altered
should participants set a quit date. All remaining ses-
sions are scheduled on the day after the selected quit
day and then every week after that. Although the opti-
mal number of sessions of MI is not known [12,17] four
sessions were chosen as a practical compromise between
having too many sessions for participants who do not
progress toward making a quit attempt and having
enough sessions to both motivate and then assist smo-
kers who do progress to making a quit attempt.
In MI counselors assist participants to explore and re-
solve ambivalence regarding quitting smoking, consist-
ent with MI principles and strategies described by Miller
& Rollnick [21]. MI emphasizes a collaborative, evoca-
tive, and autonomy supportive counseling approach,
using specific communication skills (open-ended ques-
tions, affirmations, reflections, and summaries) to ex-
press empathy, develop discrepancy between client
goals/values and current behavior, increase change talk,
and “roll with” statements of resistance to change. MI
sessions are characterized by a collaborative, interactive
counseling style in which participants are engaged in the
process of thinking and talking about their smoking be-
havior through the counselors’ use of strategic reflective
listening and occasional open-ended questions and sum-
maries. In MI, providing information on health-risks and
the benefits of quitting is minimized and offered by
counselors only when the participant asks for or appears
clearly interested in the information.
Participants who express interest in quitting receive a
self-help guide for quitting and, consistent with MI
methods for strengthening commitment for change, are
encouraged to develop a 5-step plan for quitting (set a
quit date, change environmental triggers, prepare for
triggers and urges, reward yourself, and use medication)
based on the Clinical Practice Guideline [15]. However,
to remain consistent with MI this step is delivered in an
MI style (i.e., maintaining the principles and specific
communication skills that characterize the MI ap-
proach). For example, counselors continue to support
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patient autonomy, use reflective listening and encourage
the participant to identify potential solutions before
offering their own suggestions or giving advice. Partici-
pants who choose to set a quit date within the period of
their planned participation in the study are offered a 12-
week supply of free pharmacotherapy for smoking cessa-
tion (described in more detail below).
Meta-analyses have indicated that manualized MI
interventions may produce poorer outcomes [14,17] so
MI is implemented without a structured guideline for
the flow of the session (with the exception of being
required to have the participant consider all 5 of the ele-
ments of the plan to quit should the participant express
interest in quitting). Counselors are trained to use the
various tools and strategies of MI as they see fit.
Health education
HE is designed to provide a plausible alternative inter-
vention to MI that is equivalent in contact time and that
can be delivered with fidelity. To match MI there are 4
HE sessions of approximately 20 minutes conducted on
the identical schedule and in the same format (phone
versus in-person) as MI. For participants who set a quit
date the schedule is altered in the same fashion as in the
MI arm.
In HE counselors deliver health education designed to
persuade participants to quit. The method of motivat-
ing participants is based on providing a strong rationale
for quitting based on the relevant risks of smoking,
rewards of quitting, and addressing the roadblocks to
quitting. These elements are consistent with the Clin-
ical Practice Guideline, which recommends the use of
the “5 R’s” (i.e., discuss patient relevant risks of smok-
ing, rewards of quitting, roadblocks to quitting, and re-
peat at each visit), but excludes the Guideline’s
recommendation to use MI principles in their delivery.
To ensure HE is distinct from MI, counselors in this
arm follow a semi-structured script and use printed
slides (when counseling is in-person) to deliver the
intervention.
The 5-part counseling protocol begins with an assess-
ment of participants’ smoking and quitting history and
their experience of common symptoms from smoking.
Counselors point out the link between participants’
current symptoms and their smoking. In the absence of
symptoms counselors underscore that the best thing that
participants can do for their health is to quit smoking.
Second, counselors describe major long-term (e.g., heart-
disease) and short-term (e.g., slower wound healing) risks
of smoking (4–5 at each session) and provide education
on one of a variety of smoking related topics (i.e., content
of cigarettes, costs of smoking, the addictive nature of
tobacco, luring of smokers by tobacco companies, and the
dangers of second-hand smoke). Third, counselors discuss
the potential rewards of quitting including short and long-
term health benefits. Fourth, counselors ask about partici-
pants’ roadblocks to quitting and provide suggestions or
counterarguments for each. Finally, counselors provide
personalized advice underscoring the importance of
cessation and ask participants if they are interested in
making a plan to quit. HE is designed to be warm and
supportive (i.e., not confrontational) but differs from MI
in that the primary focus is on giving information rather
than eliciting participant engagement in considering their
smoking behavior. Participants are engaged with a few
specific questions that are used to guide counselors in
providing appropriate information (e.g., suggestions for
overcoming the specific roadblocks mentioned by the
participant).
As with the MI arm, participants who express interest
in quitting receive a self-help guide for quitting, and are
encouraged to develop a 5-step plan for quitting based
on the Clinical Practice Guideline [15]. Participants who
choose to set a quit date within the period of their
planned participation in the study are offered a 12-week
supply of free pharmacotherapy for smoking cessation.
Brief advice
BA is designed to mimic usual care and provide a com-
parison treatment that is consistent with that used in
many prior MI studies for smokers [12,22]. The design of
BA is based on the recommendations of the Clinical Prac-
tice Guideline [15]. Participants meet with a counselor for
approximately 5 minutes during which they are asked
about common smoking related symptoms and are pro-
vided with clear, strong, personalized advice to quit. Smo-
kers are then asked if they are interested in quitting and, if
so, are provided with a self-help guide to quitting and
asked about their planned quit date. Participants who
choose to set a quit date within the period of their planned
participation in the study are offered a 12-week supply of
free pharmacotherapy for smoking cessation.
Provision of pharmacotherapy
All participants who set a quit date are offered pharma-
cotherapy to assist with their quit attempt to meet
standard of care. Due to evidence of its potentially su-
perior efficacy [23-25], counselors encourage the use of
varenicline (ChantixW) when not contra-indicated. Parti-
cipants who cannot or who do not wish to use vareni-
cline are offered nicotine replacement therapy in the
form of the patch or the lozenge. To avoid free medica-
tion serving as the primary motivator for smokers to
quit, medication is not mentioned or offered to partici-
pants until after they have demonstrated a commitment
to make a quit attempt by setting a quit date.
Participants who decide to use varenicline are provided
with a 12-week supply (a starter pack and 2 continuation
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packs). Participants who choose chose the patch receive
an 8 week supply if they smoke less than 10 cigarettes per
day (14 mg for 6 weeks, 7 mg for last 2 weeks), a 10 week
supply if they smoke 10 to 39 cigarettes per day (21 mg
for 6 weeks, 14 mg for 2 weeks, 7 mg for 2 weeks), and a
10 week supply if they smoke 40 or more cigarettes per
day (42 mg for 6 weeks, 28 mg for 2 weeks, and 14 mg for
2 weeks). Participants who choose the lozenge receive a
12-week supply (2 mg if they smoke their first cigarette 30
minutes after waking and 4 mg if they smoke within 30
minutes of waking). Participants are given instructions for
the proper use of their medications at the time that medi-
cations are dispensed. Participants who decide to use
medications during a phone counseling session are sched-
uled for a brief medication-dispensing visit. Participants
with cautions for using varenicline (e.g., history of depres-
sion) are monitored closely for adverse events by means of
weekly phone calls.
Interventionists and training
Three Master’s level health professionals with prior
training and experience using MI are trained to deliver
all 3 interventions to eliminate any potential of con-
founding across arms due to counselor specific effects.
The use of dedicated, specifically trained staff (as
opposed to nurse or physician providers for example) is
necessary because of the complexity of delivering all
three of these treatments with high fidelity. While this
diminishes generalizability of the results to primary care,
meta-analyses suggest that the effects of MI are at least
similar [13], if not improved, when delivered by general
practitioners [12].
Training for MI consisted of refresher training in the
practice and principles of MI through reading materials,
video demonstrations, and a half-day training workshop;
training in the MI protocol for the study (i.e., procedures
and requirements for implementing MI in this study);
and completion of role-play practice sessions with feed-
back from the MI arm supervisor in a group setting
(i.e., with all counselors present). Counselors then prac-
ticed the MI protocol with pilot participants and received
group supervision until they met criterion on rating scales
designed for fidelity monitoring (described below) for 3
consecutive sessions.
Training for HE and BA was similar, including training
in the HE and BA protocols for the study (i.e., proce-
dures and content for implementing HE and BA in this
study) and completion of role-play and pilot participant
practice sessions accompanied by group supervision
until 3 consecutive sessions met criterion.
Fidelity assurance procedures
All counseling sessions in the study are digitally
recorded. Counselors alternate in receiving regular
group supervision by separate expert supervisors (weekly
for MI, every other week for HE, and monthly for BA).
For each supervision session an audio-file is either ran-
domly selected from those completed by the counselor
since their last supervision session, or the counselor
identifies a challenging session that they wish to receive
feedback on. The supervisor provides verbal feedback as
the group listens to the session and rates adherence to
the respective protocols using rating scales adapted for
this study. The rating scales assess procedural and con-
tent requirements for each arm. For example, the MI
rating scales assess completion of basic procedures
(e.g., remind the participant that the session is being
audio recorded) and fidelity on 13 elements of MI
(e.g., uses reflective listening, rolls with resistance vs. con-
fronting, affirms and builds efficacy) and 1 global rating
(how well did the counselor conduct the session). HE and
BA rating scales similarly assess fidelity on basic procedures
and key counseling elements (e.g., providing personalized
advice, recommending quitting, linking participants’ symp-
toms to smoking). To externally verify that MI and HE
sessions differ as expected, 10% of the MI and HE sessions
(excluding those sessions that involve making quit plans
which are expected to be quite similar) are randomly
selected for coding on adherence to MI principles using
the Motivational Interviewing Treatment Integrity code
[26] by an expert independent coding group. Coders are
blind to the study arm of the session and the study hy-
potheses. We anticipate that MI sessions will receive
scores of 4 or higher on the 1–5 global rating and be
significantly higher than HE sessions on ratings of evo-
cation, collaboration, empathy, and autonomy support.
With respect to frequency measures of counselor behav-
ior we expect MI sessions to have a higher reflection to
question ratio and significantly fewer instances of giving
information.
Randomization
Prior to starting enrollment a computer-generated
randomization sequence was created by the project statis-
tician that determines whether subjects will receive MI,
HE, or BA in accordance with the 2:2:1 allocation ratio.
The statistician used sequentially numbered opaque envel-
opes to conceal the group assignment sequence until
randomization. Once eligibility is confirmed participants
complete the informed consent process. The research as-
sistant then opens the next numbered envelope in the se-
quence to reveal the participant’s group assignment and
the participant begins the computerized baseline survey.
In this manner all study personnel remain blind to the
condition to which the participant is assigned until after
participant’s eligibility is determined and informed con-
sent is obtained.
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Measures
Participants complete computer-administered assess-
ments at baseline, week 12, and 6-month follow-up.
Baseline variables include socio-demographic character-
istics (gender, age, education, employment), smoking
characteristics (cigarettes smoked per day, number of
years smoking, number of prior quit attempts), level of
nicotine dependence using the Severity of Dependence
Scale [27], and single item measures of motivation and
confidence to quit [28-30]. The primary outcome meas-
ure is the occurrence of any quit attempt defined as a
serious quit attempt of at least 24 hours [31] by
6-month follow-up. The secondary outcome is biochem-
ically verified 7-day point-prevalence abstinence at
6-month follow-up [32,33]. Biochemical verification is
conducted by research staff using cotinine test strips for
saliva [34]. Hypothesized mediators of MI’s effect on quit
attempts are autonomous motivation and autonomy
support which are assessed using the Treatment Self-
Regulation Questionnaire [35] and the Health Care
Climate questionnaire [36,37], respectively. For those
who decide to make a quit attempt, weeks of pharma-
cotherapy use is assessed with a self-report checklist
[29] and will be examined as a mediator of MI’s effect
on cessation.
Reimbursement
Participants receive compensation for time and travel in
the form of payment for each survey and counseling ses-
sion completed (i.e., $30 for completing baseline and
week 12 surveys, $50 for the 6-month follow-up surveys
and $10 for each counseling session). Total compensa-
tion is up to $120 for BA and $150 for MI and HE.
Analyses
Power and sample size
Sample size calculations are based on planned compari-
sons of quit attempts between MI and HE, and MI and
BA, and based on conservative (i.e., high) estimates of a
15% and 30% quit attempt rate in the BA and HE arm
respectively. The calculations are based on a two-tailed
test with an alpha of .05 and a power level of 80%, and
an estimated attrition rate of 25%. A sample of 102 per
group is necessary to detect a difference of 25% in the
proportion of subjects making a 24 hour quit attempt
between MI and HE groups, and a sample of 51 per
group is necessary to detect a difference of 40% between
MI and BA groups. To conserve resources, the study is
not powered for all three pairwise comparisons allowing
for a smaller BA sample size and the 2:2:1 allocation
ratio. For the same reason, the study focuses on building
motivation and generating quit attempts and is not pow-
ered for the secondary aim of determining group differ-
ences in 7-day point prevalence abstinence. The trial
aims to obtain effect-size estimates for the MI interven-
tion relative to HE and BA on cessation that will inform
future studies. Based on the 2:2:1 allocation ratio the
target sample is therefore 255 (102 MI, 102 HE, and
51 BA).
Data analyses
All analyses will be conducted in an intent-to-treat man-
ner. Our primary analyses will utilize a planned compari-
sons approach to compare the proportion of those
making at least one quit attempt for HE and MI, and for
BA and MI, using logistic regression. If preliminary ana-
lyses comparing groups on baseline variables suggest po-
tential confounding effects by any covariate, these will
be included in the logistic regression models. For the
secondary hypotheses we will also use logistic regression
to compare the effectiveness of HE and MI, and MI and
BA, on 7-day point prevalence abstinence at follow-up.
To evaluate autonomy support and autonomous regula-
tion as mediators of the presumed effect of MI on quit
attempts, and weeks of pharmacotherapy use as a medi-
ator of the presumed effect of MI on cessation, we will
follow the procedural steps outlined by Baron and
Kenny [38] using logistic regression and the Sobel test
[39,40].
Discussion
Although MI is a promising tool for healthcare providers
who regularly encounter low motivated smokers, stron-
ger evidence for its efficacy is needed to justify the add-
itional training and maintenance of skills needed for this
approach. This study is designed to provide the most
rigorous evaluation of MI to date, focusing specifically
on smokers not motivated to quit and examining quit
attempts as the primary outcome. Examination of quit
attempts rather than cessation conserves resources but
will provide a strong preliminary indication of the po-
tential efficacy of MI for tobacco treatment in this popu-
lation. A much larger sample size would be necessary to
power a trial in which cessation is the primary outcome.
However, the secondary outcome of smoking cessation
at 6-month follow-up in this study will provide an effect
size estimate that can inform the design of future MI
trials focused on cessation. On the other hand, should
MI fail to prove more efficacious than brief advice or
health education, it would encourage reconsideration of
the current Clinical Practice Guideline and prompt fur-
ther research to develop more powerful intervention
methods to motivate smokers to try to quit.
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